Preetesh Jain

M.D. Anderson Cancer Center

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

NIH RePORTER

Trial papers

102

PubMed author-name match

Trials

Studies that name Preetesh Jain as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:24 UTC. Open this list on ClinicalTrials.gov

Ph2
NCT07257055 · Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
M.D. Anderson Cancer Center · recruiting · Phase 2 Study, MCL, BTKi · principal investigator
Ph2
NCT05529069 · Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center · recruiting · Mantle Cell Lymphoma, Non Hodgkin Lymphoma, Hematologic Malignancy · principal investigator
Early Ph1
NCT05495464 · A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
M.D. Anderson Cancer Center · active not recruiting · Lymphoma, Mantle Cell Lymphoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 22:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:24 UTC. The ranking covers the 200 most relevant of 102 PubMed records, and a shared surname and initials can bring in a namesake. All 102 on PubMed

Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure.
Hepatology · 2020
160 citations
RCR 9.7
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).
Circulation · 2016
158 citations
RCR 5.7
Delayed internal fixation of fractures of the neck of the femur in young adults. A prospective, randomised study comparing closed and open reduction.
J Bone Joint Surg Br · 2004
153 citations
RCR 6.7
Randomised clinical trial of synbiotic therapy in elective surgical patients.
Gut · 2004
140 citations
RCR 3.8
Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomised controlled trial.
Clin Nutr · 2004
134 citations
RCR 3.7
Randomized clinical trial investigating the use of drains and fibrin sealant following surgery for breast cancer.
Br J Surg · 2004
129 citations
RCR 5.4
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.
Blood · 2016
125 citations
RCR 4.4
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.
Blood · 2013
119 citations
RCR 3.4
The National Lung Matrix Trial of personalized therapy in lung cancer.
Nature · 2020
114 citations
RCR 3.4
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
Blood Adv · 2019
102 citations
RCR 4.5